Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2004-2005
Reliability:
1 (reliable without restriction)

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2005
Report date:
2005

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
Version / remarks:
and B 43
GLP compliance:
yes (incl. QA statement)
Limit test:
no

Test material

Reference
Name:
Unnamed
Type:
Constituent

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Breeder: Janvier, Le Genest-Saint-Isle, France
- Age at study initiation: 6 weeks
- Weight at study initiation: males: 216-246 g
females: 160-190 g
- Fasting period before study: none
- Housing: individually in suspended wire-mesh cages (43 x 21.5 x 18 cm)
with metal trays, containing autoclaved sawdust (SICSA) as bedding, under the cages
- Diet (e.g. ad libitum): ad libitum, SSNIFF R/M-H pelleted maintenance diet by SSNIFF Spezialdiäten GmbH, Germany
- Water (e.g. ad libitum): ad libitum, drinking water, filtered
- Acclimation period: 7 days


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2 C
- Humidity (%): 50 % ± 20%
- Air changes (per hr): 12 / hour (filtered, non-recycled air)
- Photoperiod (hrs dark / hrs light): 12/12 h (7:00-19:00)

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
other: MC (methyl cellulose) 0,5 %
Details on oral exposure:
PREPARATION OF DOSING SOLUTIONS:
suspension of test item in the vehicle (methylcellulose 0.5 % in purified water)
dose levels: 50, 150, 300 mg / kg / day
dosage volume: 5 ml / kg / day (constant)

VEHICLE
- Justification for use and choice of vehicle (if other than water): for solubility in water
- Concentration in vehicle: 10, 30, 60 mg / ml
- Amount of vehicle (if gavage): 5 ml / kg
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
- homogenicity and stability checked at 1 and 60 mg/ml for 9 days at +4 ºC.
-concentrations of dosage preparation checked in week 1 and 4.
- all concentrations within the theoretical range ± 10 %.
-preparations at 1 and 60 mg/ml stable and homogenous for nine days at +4 ºC
Duration of treatment / exposure:
29 days
Frequency of treatment:
daily
Doses / concentrations
Remarks:
Doses / Concentrations:
dose levels: 50, 150, 300 mg / kg / day dosage volume: 5 ml / kg / day (constant)
Basis:
other: gavage
No. of animals per sex per dose:
dose No. of animals / sex
0 (control) 5 (+2 satellites)
50 5 (+6 satellites)
150 5 (+6 satellites)
300 5 (+6 satellites)
Control animals:
yes, concurrent vehicle
Positive control:
No.

Examinations

Observations and examinations performed and frequency:
Mortality check (daily)
Clinical observation (daily)
FOB (end of period)
Body weight and food intake (weekly)
Hematology-clinical chemistry (end of period)
Sacrifice and pathology:
Organ weights-macroscope and microscope examinations.
Other examinations:
-Monitoring of estrous cycle (end of period)
-Toxicokinetics (satellite animals): day 1 and week 4.
-Sperm count, motility, morphology.
Statistics:
Yes (decision tree according to data set).

Results and discussion

Results of examinations

Clinical signs:
effects observed, treatment-related
Mortality:
mortality observed, treatment-related
Body weight and weight changes:
effects observed, treatment-related
Food consumption and compound intake (if feeding study):
effects observed, treatment-related
Food efficiency:
not specified
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
no effects observed
Clinical biochemistry findings:
effects observed, treatment-related
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Organ weight findings including organ / body weight ratios:
effects observed, treatment-related
Gross pathological findings:
no effects observed
Histopathological findings: non-neoplastic:
effects observed, treatment-related
Histopathological findings: neoplastic:
not examined
Details on results:
Clinical signs and mortality: No mortality. Clinical sings at 300 mg/kg including piloerection, hunched posture, thin appearance, soiled regions, cold to the touch and/or ptyalism. No salient finding at neurologic observation (FOB).
Body weight and gain: affected at 300 mg/kg.
Food consumption and compound intake: affected at 300 mg/kg.
Haematology: No salient changes.
Clinical chemistry: Slightly high colesterol (x1,3) and bilirubin (x1,7) serum concentration at 300 mg/kg.
Neurobehaviour: No abnormalities (FOB).
Organ wights: increased liver weight at 150 mg/kg (x1,2) and 300 mg/kg (x1,5).
Gross pathology: no salient findings.
Histopathology: non-neoplastic centrilobular hepatocellular hypertrophy at 150 and 300 mg/kg. No changes in vaginal cyclic
nor in sperm count and morphology.

Effect levels

Dose descriptor:
NOEL
Effect level:
50 mg/kg bw/day (actual dose received)
Sex:
male/female
Basis for effect level:
other: -centrilobular hepatocellular hypertrophy from 150 mg/kg/day -clinical signs and effects on BW, FC at 300 mg/kg/day

Target system / organ toxicity

Critical effects observed:
not specified

Applicant's summary and conclusion